Lunai Bioworks Showcases AI Platform for Drug Discovery and Biodefense on CNBC

The company's CEO discusses how the platform is accelerating therapeutic innovation and strengthening biodefense preparedness.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Lunai Bioworks, an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery for central nervous system disorders and advance biodefense countermeasures against emerging chemical and biological threats.

Why it matters

Lunai's appearance on CNBC underscores the growing investor interest in scalable AI platforms that can transform drug development and bolster national security-focused biodefense efforts. The company's technology aims to accelerate the discovery of novel treatments for complex neurological disorders and strengthen preparedness against future biological threats.

The details

During the CNBC segment, Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across CNS therapeutics and biodefense programs. The company is actively engaging with leading pharmaceutical companies and government agencies around its biotech and biodefense capabilities.

  • Lunai Bioworks was featured on CNBC's Business Minute on February 13, 2026.

The players

Lunai Bioworks

An AI-powered biotech and biodefense company that is pioneering safe and responsible generative biotechnology.

David Weinstein

The Chief Executive Officer of Lunai Bioworks.

Got photos? Submit your photos here. ›

What they’re saying

“We are deploying AI to accelerate discovery in CNS disease and biodefense. Our platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently.”

— David Weinstein, Chief Executive Officer (CNBC)

What’s next

Lunai Bioworks is actively advancing discussions with leading pharmaceutical companies and government agencies around both their biotech and biodefense capabilities.

The takeaway

Lunai Bioworks' appearance on CNBC highlights the growing importance of scalable AI platforms in accelerating drug discovery and strengthening biodefense preparedness. The company's technology aims to drive innovation in central nervous system therapeutics and provide critical countermeasures against emerging biological threats.